Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$377K Sell
5,602
-3,034
-35% -$202K ﹤0.01% 1176
2026
Q1
$542K Buy
8,636
+43
+0.5% +$2.99K 0.01% 896
2025
Q4
$576K Buy
8,593
+675
+9% +$43.6K 0.01% 859
2025
Q3
$533K Sell
7,918
-1,082
-12% -$85.6K 0.01% 897
2025
Q2
$786K Sell
9,000
-131
-1% -$10.3K 0.01% 681
2025
Q1
$624K Sell
9,131
-1,179
-11% -$96.2K 0.01% 735
2024
Q4
$804K Sell
10,310
-112
-1% -$8.29K 0.01% 666
2024
Q3
$690K Buy
10,422
+252
+2% +$20.7K 0.01% 745
2024
Q2
$1.14M Buy
+10,170
New +$1.29M 0.02% 483

Other funds holding DXCM

Choreo LLC's DXCM Position: Q2 2026 in Review

Choreo LLC reduced its DexCom (DXCM) stake by 35% in Q2 2026, selling an estimated $202K and leaving 5,602 shares worth $377K. The position accounts for ﹤0.01% of the portfolio, ranked #1176.

Choreo LLC first reported a position in DXCM in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.14M in Q2 2024. 968 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Choreo LLC held 5,602 shares of DexCom worth $377K as of Q2 2026.
  • Choreo LLC sold 3,034 DexCom shares in Q2 2026, an estimated $202K.
  • DexCom made up ﹤0.01% of Choreo LLC's portfolio in Q2 2026, its #1176 holding.
  • Choreo LLC first reported a position in DexCom in Q2 2024 and has held it in 9 quarters since.
  • Choreo LLC's DexCom position peaked at $1.14M in Q2 2024.
  • 968 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Choreo LLC's 13F filing for Q2 2026, filed 4 Aug 2026.